Managing myeloma kidney

Morie A. Gertz

doi:10.7326/0003-4819-143-11-200512060-00013

Managing myeloma kidney

Morie A. Gertz

Hematology

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

Renal insufficiency is a challenging clinical problem in patients with multiple myeloma. The standard therapy has been plasma exchange, which reduces serum light chain levels while chemotherapy reduces the number of light chain-secreting malignant plasma cells. In this issue, Clark and colleagues' study challenges this widely held standard of patient management.

Original language	English (US)
Pages (from-to)	835-837
Number of pages	3
Journal	Annals of internal medicine
Volume	143
Issue number	11
DOIs	https://doi.org/10.7326/0003-4819-143-11-200512060-00013
State	Published - Dec 6 2005

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.7326/0003-4819-143-11-200512060-00013

Cite this

@article{aae760469f974524900f856f9d5ec6f8,

title = "Managing myeloma kidney",

abstract = "Renal insufficiency is a challenging clinical problem in patients with multiple myeloma. The standard therapy has been plasma exchange, which reduces serum light chain levels while chemotherapy reduces the number of light chain-secreting malignant plasma cells. In this issue, Clark and colleagues' study challenges this widely held standard of patient management.",

author = "Gertz, {Morie A.}",

year = "2005",

month = dec,

day = "6",

doi = "10.7326/0003-4819-143-11-200512060-00013",

language = "English (US)",

volume = "143",

pages = "835--837",

journal = "Annals of internal medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "11",

}

TY - JOUR

T1 - Managing myeloma kidney

AU - Gertz, Morie A.

PY - 2005/12/6

Y1 - 2005/12/6

N2 - Renal insufficiency is a challenging clinical problem in patients with multiple myeloma. The standard therapy has been plasma exchange, which reduces serum light chain levels while chemotherapy reduces the number of light chain-secreting malignant plasma cells. In this issue, Clark and colleagues' study challenges this widely held standard of patient management.

AB - Renal insufficiency is a challenging clinical problem in patients with multiple myeloma. The standard therapy has been plasma exchange, which reduces serum light chain levels while chemotherapy reduces the number of light chain-secreting malignant plasma cells. In this issue, Clark and colleagues' study challenges this widely held standard of patient management.

UR - http://www.scopus.com/inward/record.url?scp=28844507526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844507526&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-143-11-200512060-00013

DO - 10.7326/0003-4819-143-11-200512060-00013

M3 - Review article

C2 - 16330796

AN - SCOPUS:28844507526

SN - 0003-4819

VL - 143

SP - 835

EP - 837

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 11

ER -

Managing myeloma kidney

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this